COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 17 FDA records to the applicant name Bolton Medical, Inc.. It includes 1 original PMA approval. 7 entries are PMA supplements. 9 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 5, 2021 to Oct 28, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MIH appears in 17 of the 17 linked filings. The collection spans 1 FDA product code and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P200045, with 9 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 799 International Pkwy., Sunrise, FL, 33325. Recorded on P200045/S025, decision dated Oct 28, 2026.
Device categories in this collection
System, Endovascular Graft, Aortic Aneurysm Treatment.
Changes described in PMA records
FDA recorded a 30-Day Notice decision coded OK30 on 2026-10-28 for supplement P200045/S025 to PMA P200045, submitted by Bolton Medical, Inc. for the RelayPro Thoracic Stent-Graft Delivery System. The supplement type is listed as a 30-Day Notice with the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the recorded statement describes combining two delivery system components into a single component for the RelayPro Thoracic Stent-Graft System.
The record covers a manufacturing process change to the delivery system rather than a new approval of the full stent-graft system, and the source does not describe the affected components, the sterilization or packaging sites involved, or any conditions attached to the decision. The device category is listed as SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT, with Cardiovascular specialty and product code MIH. No supporting documents were included, so the basis for OK30 and any clinical implications remain unknown from this record.
FDA approval-order wording
combination of two delivery system components into a single component for the RelayPro Thoracic Stent-Graft System
Oct 28, 2026 · 30-Day NoticeFDA’s recorded scope: addition of a routine bacterial endotoxin testing facility for the RelayPro Thoracic Stent-Graft System and the TREO Abdominal Stent-Graft System
Jun 18, 2026 · 30-Day NoticeFDA’s recorded scope: addition of a routine bacterial endotoxin testing facility for the RelayPro Thoracic Stent-Graft System and the TREO Abdominal Stent-Graft System
Jun 18, 2026 · 30-Day NoticeFDA’s recorded scope: Approval for a change in the inner liner material of the introducer sheath for the RelayPro Thoracic Stent-Graft System and TREO Abdominal Stent-Graft System.
Apr 13, 2026 · Normal 180 Day TrackFDA’s recorded scope: Approval for a change in the inner liner material of the introducer sheath for the RelayPro Thoracic Stent-Graft System and TREO Abdominal Stent-Graft System.
Apr 13, 2026 · Normal 180 Day TrackSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.